Livforsakringsbolaget Skandia’s PDL BioPharma, Inc. PDLI Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-59,700	Closed	-$301K	–	732
2015 Q3	$301K	Hold	59,700	–	–	0.02%	641
2015 Q2	$384K	Hold	59,700	–	–	0.02%	628
2015 Q1	$420K	Hold	59,700	–	–	0.02%	623
2014 Q4	$460K	Hold	59,700	–	–	0.02%	621
2014 Q3	$446K	Hold	59,700	–	–	0.02%	625
2014 Q2	$578K	Hold	59,700	–	–	0.02%	612
2014 Q1	$496K	Buy	+59,700	New	+$512K	0.02%	621

Other funds holding PDLI

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Livforsakringsbolaget Skandia's PDLI Position: Q4 2015 in Review

Livforsakringsbolaget Skandia sold out of PDL BioPharma, Inc. (PDLI) in Q4 2015, closing a stake of 59,700 shares — an estimated $301K sold.

Livforsakringsbolaget Skandia first reported a position in PDLI in Q1 2014 and held it in 7 quarters. The position peaked at $578K in Q2 2014. 204 funds tracked by Wall St. Rank hold PDLI as of Q4 2015.

Livforsakringsbolaget Skandia reported no remaining PDL BioPharma, Inc. position as of Q4 2015 after selling out during the quarter.
Livforsakringsbolaget Skandia sold 59,700 PDL BioPharma, Inc. shares in Q4 2015, an estimated $301K.
Livforsakringsbolaget Skandia first reported a position in PDL BioPharma, Inc. in Q1 2014 and held it in 7 quarters.
Livforsakringsbolaget Skandia's PDL BioPharma, Inc. position peaked at $578K in Q2 2014.
204 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2015.

Based on Livforsakringsbolaget Skandia's 13F filing for Q4 2015, filed 21 Jan 2016.